CeriBell (NASDAQ:CBLL) Director Sells $13,786.09 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Rebecca Robertson sold 827 shares of the stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $16.67, for a total transaction of $13,786.09. Following the sale, the director directly owned 8,388 shares in the company, valued at $139,827.96. This trade represents a 8.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

CeriBell Stock Up 7.0%

NASDAQ:CBLL traded up $1.26 on Thursday, reaching $19.26. 459,899 shares of the stock traded hands, compared to its average volume of 301,834. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $714.36 million, a price-to-earnings ratio of -12.73 and a beta of 1.35. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $32.75. The company’s fifty day simple moving average is $13.12 and its 200 day simple moving average is $14.37.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.06. The company had revenue of $22.59 million during the quarter, compared to the consensus estimate of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. Equities analysts predict that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CBLL shares. TD Cowen dropped their price objective on CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. JPMorgan Chase & Co. reduced their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Finally, Raymond James Financial assumed coverage on CeriBell in a research note on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.17.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Deutsche Bank AG raised its position in CeriBell by 0.4% during the first quarter. Deutsche Bank AG now owns 231,629 shares of the company’s stock valued at $4,450,000 after purchasing an additional 842 shares during the period. CenterBook Partners LP purchased a new stake in CeriBell during the 1st quarter valued at $3,531,000. Swiss National Bank bought a new stake in CeriBell in the first quarter worth $467,000. Nuveen LLC bought a new position in CeriBell during the first quarter valued at $311,000. Finally, Lord Abbett & CO. LLC raised its stake in shares of CeriBell by 7.9% in the first quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company’s stock valued at $6,138,000 after acquiring an additional 23,451 shares during the period.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.